The latest update is out from Cantargia AB ( (SE:CANTA) ).
Cantargia AB has published preclinical data demonstrating that targeting IL1RAP with nadunolimab can effectively counteract tumor-induced systemic immune suppression in cancer. The findings, published in Cancer Discovery, show that blocking IL1RAP can overcome resistance to immune therapy, particularly in cervical cancer models, and enhance the efficacy of cancer vaccines. Clinical data further supports nadunolimab’s potential to improve immunotherapy outcomes, highlighting its significance in cancer treatment and its potential impact on patient prognosis.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the IL1RAP protein, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program, nadunolimab (CAN04), is being studied in combination with chemotherapy, targeting pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Their second program, CAN10, targets autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.